NCT03454165View on ClinicalTrials.gov

A Study of BNC105P Combined With Ibrutinib

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

January 14, 2021

Study Completion Date

January 14, 2021

Conditions
Chronic Lymphocytic Leukemia
Interventions
COMBINATION_PRODUCT

BNC105P

BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.

COMBINATION_PRODUCT

Ibrutinib

A novel BTK inhibitor.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT03454165 - A Study of BNC105P Combined With Ibrutinib | Biotech Hunter | Biotech Hunter